{"title":"Community Pharmacists' Perspectives and Experiences of Deprescribing in Québec, Canada: Findings From a Survey","authors":"Alexandre Campeau Calfat, Béatrice Martin, Caroline Sirois","doi":"10.1111/bcpt.70328","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Community pharmacists in Quebec can bill for deprescribing. However, uptake remains low. We aimed to explore how community pharmacists perceive and engage in deprescribing.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Community pharmacists were invited to complete an online survey through a pharmacists' social media group and a newsletter. Data were analysed using descriptive statistics and univariate chi-square tests.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 366 respondents, most were women (<i>n</i> = 269; 74%), worked full-time (<i>n</i> = 282; 77%), had time for clinical interventions (<i>n</i> = 223; 61%), while 53% (<i>n</i> = 193) had fewer than 11 years of experience. Three quarters (<i>n</i> = 271) reported initiating deprescribing at least monthly. Side effects (<i>n</i> = 273; 75%) and patients' requests (<i>n</i> = 220; 60%) were more common reasons for deprescribing. More than 70% (<i>n</i> = 268) reported that prescribers usually accepted recommendations. Initial and follow-up consultations were systematically billed by 50% (<i>n</i> = 183) and 48% (<i>n</i> = 174) of respondents, respectively. Deprescribing interventions and billing practices were more common among pharmacists with dedicated clinical time and those working full time (all <i>p</i> < 0.01). Main barriers to billing were insufficient training (<i>n</i> = 217; 59%), uncertainty about reimbursement eligibility (<i>n</i> = 127; 35%) and lack of time (<i>n</i> = 112; 31%). Integrated software was the most common facilitator (<i>n</i> = 246; 67%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Deprescribing was commonly reported among respondents and was often prompted by clinical concerns and patient requests. Billing uncertainties and time constraints remained important barriers, highlighting opportunities to better support deprescribing in community pharmacy.</p>\n </section>\n </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 6","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70328","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70328","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Community pharmacists in Quebec can bill for deprescribing. However, uptake remains low. We aimed to explore how community pharmacists perceive and engage in deprescribing.
Methods
Community pharmacists were invited to complete an online survey through a pharmacists' social media group and a newsletter. Data were analysed using descriptive statistics and univariate chi-square tests.
Results
Among 366 respondents, most were women (n = 269; 74%), worked full-time (n = 282; 77%), had time for clinical interventions (n = 223; 61%), while 53% (n = 193) had fewer than 11 years of experience. Three quarters (n = 271) reported initiating deprescribing at least monthly. Side effects (n = 273; 75%) and patients' requests (n = 220; 60%) were more common reasons for deprescribing. More than 70% (n = 268) reported that prescribers usually accepted recommendations. Initial and follow-up consultations were systematically billed by 50% (n = 183) and 48% (n = 174) of respondents, respectively. Deprescribing interventions and billing practices were more common among pharmacists with dedicated clinical time and those working full time (all p < 0.01). Main barriers to billing were insufficient training (n = 217; 59%), uncertainty about reimbursement eligibility (n = 127; 35%) and lack of time (n = 112; 31%). Integrated software was the most common facilitator (n = 246; 67%).
Conclusion
Deprescribing was commonly reported among respondents and was often prompted by clinical concerns and patient requests. Billing uncertainties and time constraints remained important barriers, highlighting opportunities to better support deprescribing in community pharmacy.
期刊介绍:
Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.